Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 (Q45957143)
Jump to navigation
Jump to search
scientific article published on 16 January 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 |
scientific article published on 16 January 2015 |
Statements
1 reference
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 (English)
1 reference
1 reference
Karim Fizazi
1 reference
Mary-Ellen Taplin
1 reference
Fred Saad
1 reference
Charles J Ryan
1 reference
Matthew R Smith
1 reference
Peter F A Mulders
1 reference
Cora N Sternberg
1 reference
Kurt Miller
1 reference
Christopher J Logothetis
1 reference
Neal D Shore
1 reference
Eric J Small
1 reference
Thomas W Flaig
1 reference
Celestia S Higano
1 reference
Paul de Souza
1 reference
Johann S de Bono
1 reference
Thomas W Griffin
1 reference
Peter De Porre
1 reference
Margaret K Yu
1 reference
Youn C Park
1 reference
Jinhui Li
1 reference
Thian Kheoh
1 reference
Vahid Naini
1 reference
Arturo Molina
1 reference
COU-AA-302 Investigators
1 reference
16 January 2015
1 reference
1 reference
16
1 reference
152-160
1 reference
2
1 reference
Identifiers
1 reference
1 reference